Last reviewed · How we verify
Methoxy-polyethyleneglycol epoetin beta
At a glance
| Generic name | Methoxy-polyethyleneglycol epoetin beta |
|---|---|
| Also known as | Mircera |
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- An Observational Study of Methoxy Polyethylene Glycol-epoetin Beta in Participants With a Kidney Transplant
- Hemoglobin Kinetics in Response to Mircera® in Patients With Acute Myocardial Infarction (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methoxy-polyethyleneglycol epoetin beta CI brief — competitive landscape report
- Methoxy-polyethyleneglycol epoetin beta updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI